Literature DB >> 28381315

Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation.

Elena Biasibetti1, Alberto Valazza1, Maria T Capucchio2, Laura Annovazzi3, Luigi Battaglia4, Daniela Chirio4, Marina Gallarate4, Marta Mellai3, Elisabetta Muntoni4, Elena Peira4, Chiara Riganti5, Davide Schiffer3, Pierpaolo Panciani6, Michele Lanotte6.   

Abstract

Research in neurooncology traditionally requires appropriate in vivo animal models, on which therapeutic strategies are tested before human trials are designed and proceed. Several reproducible animal experimental models, in which human physiologic conditions can be mimicked, are available for studying glioblastoma multiforme. In an ideal rat model, the tumor is of glial origin, grows in predictable and reproducible patterns, closely resembles human gliomas histopathologically, and is weakly or nonimmunogenic. In the current study, we used MRI and histopathologic evaluation to compare the most widely used allogeneic rat glioma model, C6-Wistar, with the F98-Fischer syngeneic rat glioma model in terms of percentage tumor growth or regression and growth rate. In vivo MRI demonstrated considerable variation in tumor volume and frequency between the 2 rat models despite the same stereotactic implantation technique. Faster and more reproducible glioma growth occurred in the immunoresponsive environment of the F98-Fischer model, because the immune response is minimized toward syngeneic cells. The marked inability of the C6-Wistar allogeneic system to generate a reproducible model and the episodes of spontaneous tumor regression with this system may have been due to the increased humoral and cellular immune responses after tumor implantation.

Entities:  

Mesh:

Year:  2017        PMID: 28381315      PMCID: PMC5402734     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  19 in total

Review 1.  Basic principles of immunological surveillance of the normal central nervous system.

Authors:  W F Hickey
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

Review 2.  Brain-immune connection: immuno-regulatory properties of CNS-resident cells.

Authors:  B Becher; A Prat; J P Antel
Journal:  Glia       Date:  2000-02-15       Impact factor: 7.452

Review 3.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

4.  Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.

Authors:  Xiaoming Zhang; Mian Guo; Lei Shen; Shaoshan Hu
Journal:  Photodiagnosis Photodyn Ther       Date:  2014-11-04       Impact factor: 3.631

Review 5.  Mouse models of glioma.

Authors:  Stanley S Stylli; Rodney B Luwor; Thomas M B Ware; Fiona Tan; Andrew H Kaye
Journal:  J Clin Neurosci       Date:  2015-02-16       Impact factor: 1.961

6.  Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy.

Authors:  A T Parsa; I Chakrabarti; P T Hurley; J H Chi; J S Hall; M G Kaiser; J N Bruce
Journal:  Neurosurgery       Date:  2000-10       Impact factor: 4.654

7.  Differentiated rat glial cell strain in tissue culture.

Authors:  P Benda; J Lightbody; G Sato; L Levine; W Sweet
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

Review 8.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

9.  Stem cells based therapy in high grade glioma: why the intraventricular route should be preferred?

Authors:  P P Panciani; M Fontanella; I Tamagno; L Battaglia; D Garbossa; G Inghirami; F Fagioli; M Pagano; A Ducati; M Lanotte
Journal:  J Neurosurg Sci       Date:  2012-09       Impact factor: 2.279

Review 10.  In vivo models of primary brain tumors: pitfalls and perspectives.

Authors:  Peter C Huszthy; Inderjit Daphu; Simone P Niclou; Daniel Stieber; Janice M Nigro; Per Ø Sakariassen; Hrvoje Miletic; Frits Thorsen; Rolf Bjerkvig
Journal:  Neuro Oncol       Date:  2012-06-07       Impact factor: 12.300

View more
  5 in total

Review 1.  Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours.

Authors:  Chiara Ferraris; Roberta Cavalli; Pier Paolo Panciani; Luigi Battaglia
Journal:  Int J Nanomedicine       Date:  2020-04-30

2.  Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration.

Authors:  Joanna Stalinska; Cecilia Vittori; Charles H Ingraham Iv; Sean C Carson; Karlie Plaisance-Bonstaff; Adam Lassak; Celeste Faia; Susan B Colley; Francesca Peruzzi; Krzysztof Reiss; Branko S Jursic
Journal:  Sci Rep       Date:  2022-03-01       Impact factor: 4.379

3.  Far-Red Fluorescent Murine Glioma Model for Accurate Assessment of Brain Tumor Progression.

Authors:  Tatiana A Mishchenko; Irina V Balalaeva; Maria O Klimenko; Anna A Brilkina; Nina N Peskova; Evgenii L Guryev; Dmitri V Krysko; Maria V Vedunova
Journal:  Cancers (Basel)       Date:  2022-08-06       Impact factor: 6.575

4.  Survival of rats bearing advanced intracerebral F 98 tumors after glutathione depletion and microbeam radiation therapy: conclusions from a pilot project.

Authors:  E Schültke; E Bräuer-Krisch; H Blattmann; H Requardt; J A Laissue; G Hildebrandt
Journal:  Radiat Oncol       Date:  2018-05-10       Impact factor: 3.481

5.  Comparison of Elemental Anomalies Following Implantation of Different Cell Lines of Glioblastoma Multiforme in the Rat Brain: A Total Reflection X-ray Fluorescence Spectroscopy Study.

Authors:  Karolina Planeta; Zuzanna Setkowicz; Natalia Janik-Olchawa; Katarzyna Matusiak; Damian Ryszawy; Agnieszka Drozdz; Krzysztof Janeczko; Beata Ostachowicz; Joanna Chwiej
Journal:  ACS Chem Neurosci       Date:  2020-11-18       Impact factor: 5.780

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.